TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03655262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unconscious Neuro-reinforcement
Description: Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete x day(s) of neuro-reinforcement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unconscious Neuro-reinforcement
Description: Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete x day(s) of neuro-reinforcement.
Study: NCT04622722

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutren Diabetes
Description: Nutren Diabetes provides energy at 360 kcal per 360 ml

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutren Diabetes
Description: Nutren Diabetes provides energy at 360 kcal per 360 ml

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isocaloric
Description: Isocaloric diet One carton of soy milk (250 ml) and bologna sandwiches (two slices of bread) with mayonnaise

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isocaloric
Description: Isocaloric diet One carton of soy milk (250 ml) and bologna sandwiches (two slices of bread) with mayonnaise
Study: NCT00632203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 5-mg, 20-mg, and 100-mg gel capsules, 75 mg/m\^2 PO daily for 21 consecutive days, followed by a 7-day rest period, until progression or up to a maximum of 6 cycles, whichever occurs first.
Study: NCT01579968

Intervention type: DRUG
Intervention: eptacog alfa (activated)
Description: Safety and effectiveness data collection in connection with the use of eptacog alpha in daily clinical practice
Study: NCT03292120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: measure of the SOFA score
Description: The Sequential Organ Failure Assessment (SOFA) Score predicts ICU mortality based on lab results and clinical data.
Study: NCT01622400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic education HTA Vasc
Description: The intervention program takes place in 3 phases. First, the education team realizes an individual educational diagnosis to define the objectives of the intervention according to each patient's needs. Secondly, patients assist to 3 to 5 group sessions lasting 2 hours with a dedicated nurse focusing on medical therapy explanation and blood pressure self measurement education - and with a dedicated nutritionist focusing on stress management and nutrition program. Patients can also have individual consultations with the dedicated nutritionist. Finally, an individual assessment permits to evaluate the benefits of the program for each patient and to define new objectives.
Study: NCT03989024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadorelin
Description: Drug: Gonadotropin-releasing Hormone. Generic name: Gonadorelin. Dosage form: 600ug. Dosage: 10ug/puls. Frequency: every 90 min. Duration: 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene
Description: Drug: Clomiphene. Generic name: Clomiphene. Dosage form: 50mg. Dosage: 50mg. Frequency: once a day. Duration: 3 months
Study: NCT03928522

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hand mixed vancomycin
Description: hand mixed vancomycin powder into cement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hand mixed vancomycin
Description: hand mixed vancomycin powder into cement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hand mixed tobramycin
Description: hand mixed tobramycin into cement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hand mixed tobramycin
Description: hand mixed tobramycin into cement
Study: NCT00811954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg taken orally once daily. A protease inhibitor (PI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: 300 mg taken orally once daily. A protease inhibitor (PI).
Study: NCT03928522

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pre-mixed tobramycin
Description: this cement is already pre-mixed with tobramycin
Study: NCT00780351

Intervention type: DEVICE
Intervention: sustained low efficiency daily hemodiafiltration (SLEDD-f)
Description: vancomycin 15mg/kg IV infusion on day 1 from 6PM to 8PM. Start SLEDD-f on day 2 from 9AM to 5PM.
Study: NCT04526067

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CAT
Description: An evidence-based psychosocial treatment using environmental supports such as signs, alarms, pill containers, and the organization of belongings established in a person's home on weekly visits to cue adaptive behaviors and establish healthy habits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: R-CAT
Description: An evidence-based psychosocial treatment using environmental supports such as signs, alarms, pill containers, and the organization of belongings established in a person's home using remote weekly visits to cue adaptive behaviors and establish healthy habits.
Study: NCT00765713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure
Description: Nocturnal
Study: NCT00003203

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 1.8 Gy/fx x 20fx=36Gy Craniospinal XRT\*
Study: NCT00927264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Intervention for ETS Reduction
Description: The intervention is designed to motivate caregivers to reduce a child's ETS exposure by establishing a complete home and car smoking ban and by considering smoking cessation. Caregivers will receive 2 home visits \& 2 telephone session, both with a health counselor. Caregivers will be provided with feedback on air nicotine levels and child salivary cotinine levels. The main target for the intervention will be the primary caregiver of the child because the primary caregiver is ultimately responsible for protecting the child from ETS exposure. Any and all household members may participate in the intervention visits but are not required to do so.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Program for ETS Reduction
Description: An Environmental Protection Agency-based educational program that will consist of information about reducing tobacco smoke exposure.
Study: NCT02641314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronomic therapy
Description: * Propranolol 0.5 mg/kgxd p.o. day 1,~  1. mg/kgxd p.o. day 2,~ 2. mg/kgxd p.o. day 3-365 (maximum total daily dose: 120 mg) divided in 2 doses per day~* Celecoxib 400 mg/m2xd p.o.; day 1-365 (maximum total daily dose: 800 mg) divided in 2 doses per day~* Cyclophosphamide cycle 1, day1: loading dose: 500 mg/m2 intravenous 1-h-infusion, single dose day 2-365 25 mg/m2xd p.o (maximum total daily dose: 50 mg) as single daily dose~* Vinblastine 3 mg/m2xd i.v. (maximum total daily dose: 6 mg) administered day 1 and 15 (every two weeks) as single daily dose~* Etoposide 25 mg/m2xd p.o.; day 1-21 weeks 1-3, 9-11, 17-19, 25-27 (maximum total daily dose: 50 mg) as single daily dose
Study: NCT02472795

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod
Description: One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod
Description: One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod
Description: One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod
Description: One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
Study: NCT04134741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinetic Control
Description: The Kinetic Control training included a functional examination of motor disorders and individual training. The KC training included active exercises, active exercises with torso muscle resistance and exercises involving lower limbs.~The duration of one training was 20-30 minutes.
Study: NCT03726333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lorlatinib
Description: continued daily administration of 100 mg lorlatinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lorlatinib
Description: continued daily administration of lorlatinib at the dose level same as Group C for the first 22 days and 100 mg QD afterwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorlatinib
Description: continued daily administration of 100 mg QD lorlatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorlatinib
Description: continued daily administration of lorlatinib at 50 mg QD initially and may be adjusted based on PK and safety results from the initial several patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorlatinib
Description: continued daily administration of lorlatinib at the dose level determined based on preliminary PK and safety results from first several patients in Group C
Study: NCT01081717

Intervention type: DRUG
Intervention: systemic non-biological treatments
Description: as prescribed

Intervention type: BIOLOGICAL
Intervention: anti-TNF biologics
Description: as prescribed

Intervention type: BIOLOGICAL
Intervention: golimumab
Description: as prescribed

Intervention type: BIOLOGICAL
Intervention: non-anti-TNF biologics
Description: as prescribed

Intervention type: OTHER
Intervention: general population
Description: non-treated cohort
Study: NCT00373490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 600 mg daily (300 mg twice daily \[b.i.d.\]) for 3 consecutive days followed by 4 days of rest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.
Study: NCT03710265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: Subjects will receive an intravenous infusion of SHR-1701 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
Study: NCT03194399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized health care service
Description: Physical activity coaching, other functional outcome observation
Study: NCT02921295

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sidekick Stubbies
Study: NCT04456959

Intervention type: DRUG
Intervention: Inotuzumab Ozogamicin
Description: Inotuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of a recombinant humanised IgG4 kappa CD22-directed monoclonal antibody (produced in Chinese hamster ovary cells by recombinant DNA technology) that is covalently linked to N-acetyl-gamma-calicheamicin dimethylhydrazide.
Study: NCT02625987

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous intradermic stitch
Description: Appendectomy wound closure with an intradermic Polyglactina 910 stitch

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Separated stitches
Description: Appendectomy wound closure with a separated stitches.
Study: NCT03811522

Intervention type: OTHER
Intervention: carbon dioxide insufflation
Description: Receives CO2 insufflation

Intervention type: OTHER
Intervention: Air insufflation
Description: Receives air insufflation
Study: NCT01575587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone: Treatment A
Description: 1000 mg abiraterone acetate administered in the fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone: Treatment B
Description: Standardized meal administered 1 hour after the 1000 mg abiraterone acetate dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone: Treatment C
Description: Standardized meal administered 2 hours before the 1000 mg abiraterone acetate dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone: Treatment D
Description: Standardized meal administered 2 hours before and 2 hours after the 1000 mg abiraterone acetate dose
Study: NCT03247751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intraocular lens
Description: Implant NIDEK intraocular lens after cataract surgery
Study: NCT02231008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02285842

Intervention type: DEVICE
Intervention: Primary hip resurfacing device
Description: CONSERVE® Press-Fit Femoral Components
Study: NCT00159120

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: maintained antipsychotic treatment vs. stepwise drug discontinuation
Description: maintained antipsychotic treatment (in low dose) vs. stepwise drug discontinuation; both supplemented by prodrome-based early intervention; 1 year

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maintained antipsychotic treatment vs. stepwise drug discontinuation
Description: maintained antipsychotic treatment (in low dose) vs. stepwise drug discontinuation; both supplemented by prodrome-based early intervention; 1 year
Study: NCT00687960

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant starch type 4 - raw
Description: Dose: 80g bar containing Resistant Starch Type 4 - raw

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant Starch Type 4 - Cooked
Description: Dose: 80g bar containing Resistant Starch Type 4 - cooked

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose
Description: Dose: 7 oz of oral glucose tolerance beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Puffed Wheat
Description: Dose: 80g bar containing puffed wheat cereal
Study: NCT00358371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flucloxacillin 250 mg
Description: Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flucloxacillin 500 mg
Description: Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose
Study: NCT02416921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight-gain Prevention
Description: A 4-week weight-gain prevention curriculum will be delivered via Facebook. Participants will be provided tips to prevent weight-gain and will be given the opportunity to engage with the peer coaches and other participants in the group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Women's Health
Description: A 4-week women's health curriculum will be delivered via Facebook. Participants will be provided tips for staying healthy and will be given the opportunity to engage with the peer coaches and other participants in the group.
Study: NCT04190680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kokkerelli Learning Street
Description: The Kokkerelli Learning Street focusses on one specific food product (kale, tomato, asparagus, pepper, strawberry, blue berry, mushroom, carrot, or leek) and consists of multiple components:~1. An introduction lesson at school. Children are introduced to the product and familiarised with growing and harvesting processes and the importance of the product regarding health.~2. A visit to a grower's farm during which children are introduced to the precise planting, growing and harvesting procedures of the product. Children are allowed to enter the facilities (e.g., the greenhouse) and observe and experience the farming of the product.~3. A cooking workshop at the facilities of Kids University for Cooking BV. Children prepare a meal with help of volunteers. After preparing the meal, children help to set the table and consume their self-prepared meal.~4. An evaluation lesson at school. Children evaluate the Learning Street together with their peers and teacher.
Study: NCT03071861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: Single dose of 10 mcg/kg Darbepoetin Alpha given IV at less than 24 hours of age

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Single dose of normal saline, IV, given at less than 24 hours of age
Study: NCT04527055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Subcitrate 120 MG Oral Tablet
Description: Bismuth Subcitrate (120 MG Oral Tablet) 1 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
Study: NCT04209530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN3835
Description: Collagenase Clostridium Histolyticum (CCH)
Study: NCT00556335

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manual aspiration
Description: air aspiration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional drainage
Description: drainage, pneumocath
Study: NCT04712266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: calculated IV insulin:Glucagon molar ratio

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: calculated IV Insulin dose infused at a constant rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: calculated IV Insulin dose infused at a constant rate
Study: NCT04197518

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: neuro trax system and a neurology test.
Description: the neurology will check the patience before and after tonsillectomy or adenotonsillectomy usung the neurotrax system, these parameters will be measured in this system : Non verbal memory, Go no go test, stroop interference, Visual spatial processing, Staged information processing speed, catch game, problem solving.
Study: NCT00805610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatocyte Transplantation
Description: Briefly, prepared hepatocytes from a single donor will be transplanted into the liver via intraportal or intrasplenic routes.
Study: NCT03674333

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Folic acid is a water soluble vitamin, required for various biological functions in human body, including metabolism of homocysteine.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - a sugar pill
Study: NCT00855387

Intervention type: OTHER
Intervention: No additional intervention than the intended major surgery in pancreas, liver, colorectal, gastric bypass and small bowel
Description: No additional intervention than the intended major surgery (liver, bile duct, pancreas, colorectal, gastric bypass and small bowel resections) comparing with costs
Study: NCT03870685

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP Block
Description: Transversus Plane block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Site Infiltration
Description: Surgical Site Infiltration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Description: liposomal bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Description: liposomal bupivacaine
Study: NCT04932044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Sleep Facilitation Program
Description: It is divided into two stages. The first stage is to provide sleep circadian rhythm training for preterm infants during hospitalization, and the second stage is to give the caregiver the nursing guidance to promote preterm infants' sleep before preterm infants discharged from the hospital. Moreover, continue to give nursing guidance and follow its implementation status within two months after discharge.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Receives routine care and provide general discharge care and nursing guidance.
Study: NCT03943147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Specified dose on specified days
Study: NCT04527055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Subcitrate 120 MG Oral Tablet
Description: Bismuth Subcitrate (120 MG Oral Tablet) 1 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus acidophilus and Bifidobacterium lactis Bb12
Description: The probiotic powder per oral twice daily for 24 weeks. The probiotic powder is named as President AB powder, which contains an approximately equal mixture of Lactobacillus acidophilus and Bifidobacterium lactis Bb12 at a concentration of \>= 10E9 CFU/mL (President Corp., Tainan, Taiwan).